Bioamber (BIOA) Given Daily Media Impact Rating of -0.01

Headlines about Bioamber (NYSE:BIOA) have been trending somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioamber earned a coverage optimism score of -0.01 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5890725256102 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern’s analysis:

A number of equities analysts recently weighed in on BIOA shares. ValuEngine raised shares of Bioamber from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. HC Wainwright lowered their target price on shares of Bioamber from $12.00 to $1.75 and set a “buy” rating for the company in a research note on Thursday, March 29th. Finally, Zacks Investment Research raised shares of Bioamber from a “sell” rating to a “hold” rating in a research note on Monday, February 19th.

NYSE BIOA traded down $0.02 during mid-day trading on Friday, reaching $0.01. 15,512,858 shares of the stock were exchanged, compared to its average volume of 2,970,016. Bioamber has a one year low of $0.01 and a one year high of $2.88. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 0.75.

Bioamber (NYSE:BIOA) last announced its earnings results on Tuesday, March 27th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. Bioamber had a negative net margin of 238.43% and a negative return on equity of 48.72%. The business had revenue of $5.40 million during the quarter, compared to the consensus estimate of $6.49 million. research analysts anticipate that Bioamber will post -0.53 EPS for the current fiscal year.

About Bioamber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Insider Buying and Selling by Quarter for Bioamber (NYSE:BIOA)

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with's FREE daily email newsletter.

Leave a Reply